Lapatinib, the first TKI approved against both HER2 and EGFR, enhanced HER2 expression in HER2-low BC cells [74], potentially transforming patients with refractory diseases into patients with tumors sensitive to trastuzumab [75,76,77,78]. The gene discussed is ERBB2; the disease is breast cancer.